Literature DB >> 14641154

Associations between glaucomatous visual field loss and participation in activities of daily living.

Geertje Noe1, John Ferraro, Ecosse Lamoureux, Julian Rait, Jill E Keeffe.   

Abstract

PURPOSE: This study investigated the association between visual field loss and participation in daily activities in individuals with glaucoma.
METHODS: Seventy-nine patients were recruited from the Royal Victorian Eye and Ear Hospital. Visual fields were assessed using the Esterman binocular visual field tests and participation in daily activities was assessed using the Impact of Vision Impairment (IVI) questionnaire. Visual acuity and contrast sensitivity were also measured.
RESULTS: There was no independent relationship between visual field loss and IVI score (r = -0.20; P = 0.09), except for the mobility domain (r = 0.25; P = 0.03). Mobility was the most affected domain of the IVI (mean = 1.2). Over a quarter of the patients reported experiencing moderate to severe restriction with mobility activities despite relatively minor binocular field loss.
CONCLUSION: Mobility is the area in which glaucoma patients encounter difficulties even when the visual field and visual acuity are relatively good. Questions related to mobility could be asked to identify those patients who need rehabilitation.

Entities:  

Mesh:

Year:  2003        PMID: 14641154     DOI: 10.1046/j.1442-9071.2003.00712.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  27 in total

Review 1.  Patient-reported outcomes (PRO's) in glaucoma: a systematic review.

Authors:  S Vandenbroeck; S De Geest; T Zeyen; I Stalmans; F Dobbels
Journal:  Eye (Lond)       Date:  2011-03-18       Impact factor: 3.775

2.  Use of an augmented-vision device for visual search by patients with tunnel vision.

Authors:  Gang Luo; Eli Peli
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-09       Impact factor: 4.799

3.  The impact of visual symptoms on the quality of life of patients with early to moderate glaucoma.

Authors:  Young Shin Kim; Myeong Yeon Yi; Young Jae Hong; Ka Hee Park
Journal:  Int Ophthalmol       Date:  2017-06-28       Impact factor: 2.031

4.  Feasibility, Patient Acceptability, and Preliminary Efficacy of a Culturally Informed, Health Promotion Program to Improve Glaucoma Medication Adherence Among African Americans: "Glaucoma Management Optimism for African Americans Living with Glaucoma" (GOAL).

Authors:  Laura E Dreer; Cynthia Owsley; Lisa Campbell; Liyan Gao; Andy Wood; Christopher A Girkin
Journal:  Curr Eye Res       Date:  2015-01-27       Impact factor: 2.424

5.  Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study.

Authors:  Roberta McKean-Cowdin; Ying Wang; Joanne Wu; Stanley P Azen; Rohit Varma
Journal:  Ophthalmology       Date:  2007-11-12       Impact factor: 12.079

6.  Five-year forecasts of the Visual Field Index (VFI) with binocular and monocular visual fields.

Authors:  Ryo Asaoka; Richard A Russell; Rizwan Malik; David F Garway-Heath; David P Crabb
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-07       Impact factor: 3.117

7.  Exploring eye movements in patients with glaucoma when viewing a driving scene.

Authors:  David P Crabb; Nicholas D Smith; Franziska G Rauscher; Catharine M Chisholm; John L Barbur; David F Edgar; David F Garway-Heath
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

8.  Visual function of egyptian children with low vision and the demographic determinants.

Authors:  Boshra Mohammed El Byoumi; Ahmed Mousa
Journal:  Middle East Afr J Ophthalmol       Date:  2010-01

Review 9.  Patient-Centered Outcome Measures to Assess Functioning in Randomized Controlled Trials of Low-Vision Rehabilitation: A Review.

Authors:  Joshua R Ehrlich; George L Spaeth; Noelle E Carlozzi; Paul P Lee
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

10.  Collision judgment when using an augmented-vision head-mounted display device.

Authors:  Gang Luo; Russell L Woods; Eli Peli
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.